您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > CH5132799
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
CH5132799
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
CH5132799图片
包装与价格:
包装价格(元)
5mg电议
10mg电议
50mg电议
200mg电议

产品介绍
CH5132799 是一种选择性 I 类 PI3K 抑制剂。 CH5132799 抑制 I 类 PI3K,尤其是 PI3Kα,IC50 为 14 nM。

Cell experiment:

The cell lines are added to the wells of 96-well plates containing 0.076 to 10,000 nM CH5132799 and incubated at 37℃. After 4 days of incubation, Cell Counting Kit-8 solution is added and, after incubation for several more hours, absorbance at 450 nm is measured with Microplate-Reader iMark. The antiproliferative activity is calculated. The IC50 values are calculated[1].

Animal experiment:

Mice[1] Female BALB-nu/nu mice (CAnN.Cg-Foxn1/CrlCrlj nu/nu) are used. A total of 4×106 to 1.2×107 cells are suspended in 100 to 200 μL serum-free culture medium and injected subcutaneously into the right flank of the mice. Tumor size is measured by using a gauge twice per week, and tumor volume (TV) is calculated. Once the tumors reach a volume of approximately 200 to 300 mm3, animals are randomized into groups (n=4 or 5 in each group) and treatment is initiated. CH5132799 and Everolimus are orally administered once a day and Trastuzumab is intravenously injected once a week.

产品描述

CH5132799 is an inhibitor of class I phosphatidylinositol 3-kinase (PI3K) with IC50 value of 14nM against PI3Kα [1].

CH5132799 shows inhibitory effect on class I PI3K with IC50 values of 0.014μM, 0.12μM, 0.5μM and 0.036μM against PI3Kα, PI3Kβ, PI3Kδ and PI3Kγ, respectively. PI3Kα is especially sensitive to CH5132799. CH5132799 is a selective inhibitor. It shows less effect on class II PI3Ks, class III PI3K and mTOR. For other 26 protein kinases, CH5132799 nearly has no inhibition with IC50 value of >10μM. CH5132799 is found to have potent antitumor activity. It exerts IC50 values of 0.2μM, 0.032μM, 0.056μM and 0.12μM in HCT116, KPL-4, T-47D and SK-OV-3 cell lines, respectively. Moreover, CH5132799 is oral available in animal models. Treatment of CH5132799 shows strong tumor regression at dose of 12.5 mg/kg in mice bearing human breast cancer xenografts [1].

References:
[1] Ohwada J, Ebiike H, Kawada H, et al. Discovery and biological activity of a novel class I PI3K inhibitor, CH5132799. Bioorganic & medicinal chemistry letters, 2011, 21(6): 1767-1772.